Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) ...

AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what ...

We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...

Investing in blue chips at 52-week lows can potentially yield significant returns if fundamentals are strong. Find out 5 high ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

The stock's fall snapped a two-day winning streak.